biostudies-literatureUnknownJoseph LGiven the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.British journal of haematologyhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC9877809biostudies-literatureSafety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease.PMC9877809Joseph LManceau SCorbasson AMeunier BCheminet GJannot ASKhimoud DLefrere FLu EArlet JBfalseSafety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease.Given the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.2022-01-01T00:00:00Z2022 Nov2025-04-25T20:13:47.466Z2025-04-06T08:15:39.863ZS-EPMC98778093635423410.1111/bjh.18547